Avid Bioservices Inc (CDMO)

[itsabouttime]

In Yahoo

Bristol-Myers Squibb is pinning its future on a new class of drugs that could be game-changers in the fight against cancer. The Street, though, may be wildly overestimating their commercial potential. Here's why.

This where bavi could help

In addition, a fair number of patients in these various clinical trials didn't show any meaningful clinical benefit from either Opdivo or Keytruda. So, the picture that's starting to emerge is that some patients respond extremely well to PD-1 inhibitors, whereas others, maybe even the majority, simply aren't good candidates for this new class of drugs.